BioCentury | Oct 20, 2017
Company News

PTAB rejects Sanofi and Regeneron's IPR request

...and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) for an inter partes review of a patent owned by Immunex Corp....
BioCentury | Sep 2, 2013
Finance

Amgen's preemptive strike

...tumors. Second mega When Amgen struck its last mega-sized deal - paying $16 billion for Immunex Corp....
BioCentury | Jul 15, 2013
Finance

Onyx, Alexion add spice

...but it did end up hitting a home run with its last mega-sized deal for Immunex Corp....
...Indeed, at the time, the consensus among investors was that Amgen had overpaid significantly for Immunex...
BioCentury | Apr 15, 2013
Clinical News

Immunex preclinical data

...blood stem cells. Clinical testing of its anti-cancer effect has just started, the company said. Immunex Corp....
BioCentury | Apr 15, 2013
Clinical News

Immunex regulatory update

...pain in patients with advanced prostate cancer that is no longer responsive to hormone therapy. Immunex Corp....
BioCentury | Apr 15, 2013
Clinical News

Immunex preclinical data

...receptor may act to regulate signaling between IL-1 and Type 1 receptor, the researchers noted. Immunex Corp....
BioCentury | Apr 15, 2013
Clinical News

Mobist FLT-3 ligand data

...are underway. The findings were presented at the American Society of Hematology in San Diego. Immunex Corp....
BioCentury | Jul 2, 2012
Strategy

Revving the engine

...researchPreviously executive director of research for inflammation at Amgen Inc. (NASDAQ:AMGN). Worked with Williams at Immunex Corp....
BioCentury | Dec 5, 2011
Regulation

A PROfessional trial

...its label since FDA issued its draft guidance on PROs in 2006. Novantrone mitoxantrone from Immunex Corp....
BioCentury | Dec 5, 2011
Company News

Amgen autoimmune news

...N.Y.), while Pfizer has rights elsewhere. Amgen acquired the patent through its 2002 acquisition of Immunex Corp....
Items per page:
1 - 10 of 820
BioCentury | Oct 20, 2017
Company News

PTAB rejects Sanofi and Regeneron's IPR request

...and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) for an inter partes review of a patent owned by Immunex Corp....
BioCentury | Sep 2, 2013
Finance

Amgen's preemptive strike

...tumors. Second mega When Amgen struck its last mega-sized deal - paying $16 billion for Immunex Corp....
BioCentury | Jul 15, 2013
Finance

Onyx, Alexion add spice

...but it did end up hitting a home run with its last mega-sized deal for Immunex Corp....
...Indeed, at the time, the consensus among investors was that Amgen had overpaid significantly for Immunex...
BioCentury | Apr 15, 2013
Clinical News

Immunex preclinical data

...blood stem cells. Clinical testing of its anti-cancer effect has just started, the company said. Immunex Corp....
BioCentury | Apr 15, 2013
Clinical News

Immunex regulatory update

...pain in patients with advanced prostate cancer that is no longer responsive to hormone therapy. Immunex Corp....
BioCentury | Apr 15, 2013
Clinical News

Immunex preclinical data

...receptor may act to regulate signaling between IL-1 and Type 1 receptor, the researchers noted. Immunex Corp....
BioCentury | Apr 15, 2013
Clinical News

Mobist FLT-3 ligand data

...are underway. The findings were presented at the American Society of Hematology in San Diego. Immunex Corp....
BioCentury | Jul 2, 2012
Strategy

Revving the engine

...researchPreviously executive director of research for inflammation at Amgen Inc. (NASDAQ:AMGN). Worked with Williams at Immunex Corp....
BioCentury | Dec 5, 2011
Regulation

A PROfessional trial

...its label since FDA issued its draft guidance on PROs in 2006. Novantrone mitoxantrone from Immunex Corp....
BioCentury | Dec 5, 2011
Company News

Amgen autoimmune news

...N.Y.), while Pfizer has rights elsewhere. Amgen acquired the patent through its 2002 acquisition of Immunex Corp....
Items per page:
1 - 10 of 820